Proactive Investors - Run By Investors For Investors

Cellmid convening global meeting of midkine researchers in Germany

Presentations on midkine therapies for cancer, kidney disease and heart failure.
heart highlighted on the human body
Key opinion leaders from twelve countries presenting on midkine research

Cellmid Limited (ASX:CDY) will be convening the 5th Midkine Symposium in Munich, Germany between 3rd and 5th May 2018.

The symposium will be a global meeting of key opinion leaders, clinicians and research scientists involved in midkine (MK) research.

READ: Cellmid strengthens its position in hair and skin care market with leading anti-ageing product

The event follows on the success of the previous four scientific meetings on midkine held in Sydney (2010), Istanbul (2012), Kyoto (2014) and Budapest (2016).

Assessing midkine antibodies in chronic heart failure

Midkine is a promising molecule in drug development. It is a heparin-binding growth factor that promotes cell growth, survival, differentiation and cell migration.

It is almost undetectable in healthy adults, however, is upregulated as part of the pathogenesis (development) of certain chronic diseases.

Munich has been chosen for the symposium as it is the home Ludwig Maximilian University (LMU), where researchers are currently assessing Cellmid’s midkine antibodies in a model of chronic heart failure.

READ: Cellmid enters exclusive distribution agreement for anti-ageing skincare product

The research at LMU is the subject of a recently filed patent application by Cellmid and is expected to deliver vital data and add to the company’s already substantial midkine asset portfolio.

Promoting interactions between midkine researchers

The symposium will host delegates from twelve countries with expertise in various therapeutic and diagnostic fields and will enhance interactions between leading researchers within the midkine community.

Previous meetings resulted in a number of collaborations that continue to provide vital progress for Cellmid’s therapeutic programs including the recently completed clinical studies carried out at the University of Gothenburg, Sweden.

The study in Sweden demonstrated that midkine is associated with prostate cancer progression and treatment resistance.

Symposium to be led by Dr Ludwig Weckbach

The symposium will be hosted by the team led by clinician scientist Dr Ludwig Weckbach, Cellmid’s research partner based at the Biomedical Center and Department of Cardiology, LMU.

Dr Weckbach will be welcoming symposium delegates as well presenting his group’s innovative discoveries demonstrating the clinical potential of therapeutic antibodies targeting midkine for chronic heart failure.

View full CDY profile View Profile

Cellmid Ltd Timeline

Related Articles

scientist in lab
February 26 2019
Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
February 26 2019
Immunotherapy treatment Clevegen is on phase I/II trial (MATINS) for metastatic tumours

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use